Date: 7 June 2018 **Sydney, Australia**

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office and Operational Office:
Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

NOXOPHARM RELEASES NYRADA CORPORATE PRESENTATION

Sydney, 7 June 2018: Noxopharm (ASX: NOX) today is holding a Public Briefing concerning its subsidiary company, Nyrada Inc, and duly releases the official corporate presentation.

Nyrada was established to hold intellectual property developed by Noxopharm that sat outside of that Company's core focus on oncology. Nyrada currently is two-thirds owned by Noxopharm.

The details of today's briefing are:

Time: 3.00 pm Thursday June 7

Place: Sofitel Sydney Wentworth Hotel, 61-101 Phillip St.

To view this presentation please visit the Noxopharm website (www.noxopharm.com) or the Nyrada,Inc. website (www.nyrada.com).

……

About Nyrada Inc

Nyrada Inc is a US-registered company based in New York, New York. It currently has a pipeline of 3 drugs assets: NYX-104 is an inhibitor of excitotoxicity intended to treat consequences of stroke, concussion and traumatic brain injury; NYX-205 is a novel anti-inflammatory; NYX-330 is a PCSK9-inhibitor intended to treat high blood LDl cholesterol levels.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy and chemotherapy. NOX66 is the first pipeline product, with later generation drug candidates under development.

Investor & Corporate Enquiries:
Prue Kelly
M: 0459 022 445
E: Prue.Kelly@nyrada.com

Company Secretary:
David Franks
T: +61 2 9299 9690
E: dfranks@fa.com.au

www.noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

Nyrada inc

- US biotechnology company (NYC-based)
- Founded on Australian R&D
- 3 first-in-class drug candidates
- All for major unmet needs
- Primary focus on drugs for brain and peripheral nerve diseases and conditions

NYX-104

NYX-205



Brain diseases

NYX-330

High cholesterol/ heart disease

We have assembled a world-leading
Scientific Advisory Board

Prof. Gary Housley
Chair of Physiology, University of New South Wales, Sydney and Founding Director of the Translational Neuroscience Facility.

Junichi Nabekura
Professor of Physiology and Neuroscience and a Vice-Director of the National Institute of Physiological Sciences (NIPS) in Okazaki, Japan.

Prof. Gilles Lambert

Professor Cell Biology and Biochemistry, La Reunion Medical School (France).

Leslie Shinobu
Board-certified neurologist
Massachusetts General Hospital and Harvard University.

NYX-104 Neuro-protectant

Objectives

To bring to market a drug that limits brain damage following

stroke

To help the **65%** of stroke survivors who suffer disability requiring assisted living

- by reducing the severity of the disability in the short-term
- by providing for faster recovery times and more complete recovery of function
- by reducing rehabilitation costs.

NYX-104 Neuro-protectant

Ischaemic stroke



LEFT BRAIN FUNCTIONS

Movement and sensation of right side of body

Understanding and expressing language

Reading and writing

Vision on the right side



RIGHT BRAIN FUNCTIONS

Movement and sensation of left side of body

Face and object recognition

Body awareness

Vision on the left side

NYX-104 Neuro-protectant against the expansion of brain death following brain damage

Stroke
Concussion
Traumatic brain injury



Original area of brain deprived of blood dies and does not recover.

Zone around the central core of damage can be recovered if blood supply restored quickly.

Undamaged brain cells die over following days/weeks to produce an area of brain death up to 6 times the original stroke area.

NYX-104 designed to block this expansion of area of brain death

NYX-104 Cost of stroke

795,000
PEOPLE EACH YEAR
in the US have a stroke

140,000
PEOPLE EACH YEAR
die from stroke in the US

STROKE ACCOUNTS FOR
1 in 19
deaths in the US

10%
recover almost completely

25%
recover with minor impairments

40%
experience moderate-severe impairment requiring special care

10%
require long-term nursing home care

15%
die shortly after stroke

STROKE COSTS
Indirect and direct medical costs
$34 billion
per year in the US

NYX-104 Neuroprotection

- Loss of blood flow to brain regions in Stroke and Traumatic Brain Injury drives dysregulation of neurochemicals, which in turn, leads to a massive loading of brain cells with ***calcium ions (Ca^{2+}*** – hundreds-fold increases) – switching on cell death signalling.



- A robotic screen identified NYX-104 as the stand-out lead compound compared with structurally-related (isoflavone) analogs, based on its effectiveness in blocking ***Ca^{2+}*** loading in a cell culture model for brain injury.





Nyrada inc

NYX-104 Neuro-protection *proof-of-concept*

Mouse model of human stroke.
2mm diameter area of brain death.







Mice given NYX-104 had ***smaller injury volumes*** compared to control mice

NYX-104 Neuro-protection *proof-of-concept*

NYX-104 treatment reduced expansion of brain injury by

56%



NYX-104 Development Program 2018-19

H1 2018

Proof of concept

- Provided proof-of-concept (mouse ischemia model)
- Confirm target and signaling pathway (well advanced)

H2 2018

H1 2019

Pre-clinical

- Study in second animal model to observe symptomatic outcome (motor function, cognitive function, behaviour)
- Standard pre-clinical studies

H2 2019

Clinical logistics

- Manufacturing scale-up for first-in-human study
- Clinical protocol design
- Regulatory approval

NYX-330 Cholesterol-lowering

Objectives

To bring to market a drug that **lowers LDL ('bad') cholesterol levels** in blood by inhibiting the blood protein

PCSK9

That will be used in combination with statin drugs:

- To lower LDL cholesterol levels to target levels in the 2/3^{rds} of patients in whom statin drugs fail to achieve target levels
- To achieve a reduction in the risk of cardiovascular disease (heart failure, stroke).

That will be:

- convenient (oral dosage form)
- cost-effective (cost to benefit ratio)

Nyrada inc

NYX-330 Cholesterol-lowering

Two main forms of cholesterol:

- LDL = low density lipoprotein
- HDL = high density lipoprotein



High levels of LDL are associated with increased risk of cardiovascular disease (heart attack and stroke)

33% (71 million) of US adults have **'at risk'** LDL levels

Only 1 in 3 'at risk' adults have LDL levels under control

** US Centers for Disease Control and Prevention*

NYX-330 Cholesterol-lowering

Statin drugs

Statin drugs are standard of care for patients with 'at risk' LDL levels. But……,

Target LDL levels are achieved in:

60% patients, leaving 40% patients still exposed to risk

Statins deliver limited cardiovascular benefit:

For every 138 'at risk' people treated for 5 years, just 1 fewer dies from heart disease

Cholesterol cycle

Cholesterol cycle.
- Liver cell makes LDL-C.
- Releases into bloodstream.
- LDL receptors on liver cell remove LDL-C from blood.
- LDL-C deposited inside liver cell and is broken down.
- Breakdown particles then re-assembled into LDL-C.

Blood protein, PCSK9, then discovered in 2005:
- Important component of cholesterol cycle
- Binds to LDL-receptor.
- Causes LDL receptor to be broken down along with LDL-C.
- High PCSK9 levels lead to fewer LDL receptors = higher LDL-C levels in blood.

Statins block cholesterol production by liver cell.

BUT…….

This leads to increased PCSK9 levels in blood.

Which leads to less LDL-C being removed from the blood.

Effectiveness of statins hampered by unwanted consequence of increased PCSK9 levels.

New strategy is to continue to use statins, but to add a second drug to block PCSK9 activity







NYX-330

Initial attempts to develop a small molecule drug to block PCSK9-LDLR binding appear to have failed.

Alternative pathway taken was to develop monoclonal antibodies against PCSK9

Repatha (Amgen) and ***Praluent*** (Sanofi/Regeneron) approved 2015.

In combination with statins, boost LDL reduction by up to additional **60%**.

→ Significant reduction in cardiovascular events.

Health benefit of anti-PCSK9 drugs validated.

But ……

limited market uptake:

- Lifetime injection every 2-4 weeks
- US$14,000 p.a. cost
- No reimbursement currently for most patients

Nyrada inc

NYX-330 *Novel PCSK9 inhibitor*



Australian chemists identify suitable binding site on PCSK9 for attachment of small molecule.

NYX-330 effectively blocks binding of PCSK9 to LDL receptor.

First-in-class PCSK9 inhibitor.

Appropriate drug-like behaviour confirmed in mice.

First-in-class, small molecule inhibitor of PCSK9.

Aim is to develop NYX-330 as:

- Once a day oral treatment
- Use in combination with statins
- Particular use in the 40% of 'at risk' patients where statins alone fail to achieve target LDL levels

Current statin sales = US$19 billion p.a.

Potential US$60 billion if all 'at-risk' patients in US were treated and achieved target LDL levels

NYX-330 *PCSK9 inhibitor*



Nyrada Business



Value Drivers

Large market size	Lack of competition	Experience	High profile	Potential inflection points
Large community problems. Substantial unmet needs	No known current neuro-protectant. No known small molecule inhibitor of PCSK9.	Board and CEO highly experienced in drug development and in running public companies in Australia and US	Three first-in-class drugs capable of achieving high profiles while still in pre-clinical development	Anticipated stream of key milestones over next 2 years

Key Metrics

Founding shareholding	▪ Noxopharm Ltd **67%** ▪ Altnia Holdings Pty Ltd **33%**
Seed Round Raise (Feb 2018)	○ $4M ○ 38 New Shareholders ○ Convertible Notes ○ Each Note = 3 Shares and 2 Options ○ If all Notes converted and Options exercised, shareholding will be: • **60%** Noxopharm • **27%** Altnia • **13%** New Shareholders

Disclaimer

- *This presentation has been prepared by Nyrada Inc (the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in the Company or as an inducement to make an offer or invitation to subscribe for or purchase any shares in the Company. No agreement to subscribe for securities in the Company will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.*

- *This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.*

- *This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.*

- *Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.*

- *Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.*

- *The information contained in this presentation has been prepared in good faith by the Company. No representation or warranty, express or implied, is made as to the accuracy, adequacy, reliability or completeness of any statements, estimates, opinions or other information contained in this presentation, any of which may change without notice. This includes, without limitation, any historical financial information, estimates and projections and other financial information derived from them. Nothing contained in this presentation is, or may be relied upon, as a promise or representation, whether as to the past or the future.*

Nyrada inc

Dr Graham Kelly
Chief Executive Officer

graham.kelly@nyrada.com